特発性頭蓋内圧亢進治療法の世界市場予測・分析2019-2023

◆英語タイトル:Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32189
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年10月26日
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、特発性頭蓋内圧亢進治療法の世界市場について調べ、特発性頭蓋内圧亢進治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、特発性頭蓋内圧亢進治療法の市場規模をセグメンテーション別(製品別(炭酸脱水酵素阻害剤、その他の薬物クラス)、)と地域別(グローバル)に分けて算出しました。Technavio社は特発性頭蓋内圧亢進治療法の世界市場規模が2019-2023期間中に年平均3%成長すると予測しています。
・サマリー
・レポートの範囲
・特発性頭蓋内圧亢進治療法の市場状況
・特発性頭蓋内圧亢進治療法の市場規模
・特発性頭蓋内圧亢進治療法の市場予測
・特発性頭蓋内圧亢進治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(炭酸脱水酵素阻害剤、その他の薬物クラス)
・特発性頭蓋内圧亢進治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Idiopathic Intracranial Hypertension Therapeutics Market: About this market
Technavio’s idiopathic intracranial hypertension market analysis considers sales from carbonic anhydrase inhibitors and other drug classes products. Our study also finds the sales of idiopathic intracranial hypertension in Asia, Europe, North America, and ROW. In 2018, the carbonic anhydrase inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as improved vision and decreased intracranial pressure and papilledema will play a significant role in the carbonic anhydrase inhibitors segment to maintain its market position. Also, our global idiopathic intracranial hypertension market report looks at factors such as rising incidences of idiopathic intracranial hypertension, increasing morbidity and mortality rates associated with heart diseases, and identification of risk factors associated with idiopathic intracranial hypertension. However, the asymptomatic nature of disease, limited patient pool, side effects associated with idiopathic intracranial hypertension therapeutics may hamper the growth of the idiopathic intracranial hypertension industry over the forecast period.
Global Idiopathic Intracranial Hypertension Therapeutics Market: Overview
Rising incidences of idiopathic intracranial hypertension
Developed economies such as the US and other countries are witnessing a high incidence of obesity and cardiovascular disorders, which has increased the patient pool for idiopathic intracranial hypertension. This has increased the need for immediate therapeutic interventions such as idiopathic intracranial hypertension therapeutics. Thus, the rising incidence of idiopathic intracranial hypertension will lead to the expansion of the global milk chocolate market at a CAGR of almost 3% during the forecast period.
Increasing number of awareness campaigns.
The global idiopathic intracranial hypertension therapeutics market is expected to benefit from the increasing number of awareness activities that are being undertaken by public and private organizations across the world. For instance, IIH UK, a forum managed by Rare Disease Europe (EURORDIS), helps patients with idiopathic intracranial hypertension in managing their condition. EURORDIS helps increase awareness about rare diseases and focuses on improving the health of patients with rare diseases. The organization conducts specialized social services and facilitates R&D and healthcare policies. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global idiopathic intracranial hypertension market during the forecast period 2019-2023, click here.
Competitive Landscape
With the presence of a few major players, the global idiopathic intracranial hypertension market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading idiopathic intracranial hypertension manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the idiopathic intracranial hypertension market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Carbonic anhydrase inhibitors – Market size and forecast 2018-2023
• Other drug classes – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing number of awareness campaigns
• Rising incidence of rare diseases
• Special drug designations
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Astellas Pharma Inc.
• Cadila Healthcare Ltd.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Mylan NV
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Carbonic anhydrase inhibitors – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Carbonic anhydrase inhibitors – Year-over-year growth 2019-2023 (%)
Exhibit 22: Other drug classes – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other drug classes – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Adoption rate of health insurance coverage among US adults with CHD and/or stroke (2019)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie Inc. – Vendor overview
Exhibit 50: AbbVie Inc. – Business segments
Exhibit 51: AbbVie Inc. – Organizational developments
Exhibit 52: AbbVie Inc. – Geographic focus
Exhibit 53: AbbVie Inc. – Key offerings
Exhibit 54: AbbVie Inc. – Key customers
Exhibit 55: Astellas Pharma Inc. – Vendor overview
Exhibit 56: Astellas Pharma Inc. – Business segments
Exhibit 57: Astellas Pharma Inc. – Organizational developments
Exhibit 58: Astellas Pharma Inc. – Geographic focus
Exhibit 59: Astellas Pharma Inc. – Key offerings
Exhibit 60: Astellas Pharma Inc. – Key customers
Exhibit 61: Cadila Healthcare Ltd. – Vendor overview
Exhibit 62: Cadila Healthcare Ltd. – Product segments
Exhibit 63: Cadila Healthcare Ltd. – Organizational developments
Exhibit 64: Cadila Healthcare Ltd. – Geographic focus
Exhibit 65: Cadila Healthcare Ltd. – Key offerings
Exhibit 66: Cadila Healthcare Ltd. – Key customers
Exhibit 67: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 68: Johnson & Johnson Services Inc. – Business segments
Exhibit 69: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 70: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 71: Johnson & Johnson Services Inc. – Segment focus
Exhibit 72: Johnson & Johnson Services Inc. – Key offerings
Exhibit 73: Johnson & Johnson Services Inc. – Key customers
Exhibit 74: Merck & Co. Inc. – Vendor overview
Exhibit 75: Merck & Co. Inc. – Business segments
Exhibit 76: Merck & Co. Inc. – Organizational developments
Exhibit 77: Merck & Co. Inc. – Geographic focus
Exhibit 78: Merck & Co. Inc. – Segment focus
Exhibit 79: Merck & Co. Inc. – Key offerings
Exhibit 80: Merck & Co. Inc. – Key customers
Exhibit 81: Mylan NV – Vendor overview
Exhibit 82: Mylan NV – Product segments
Exhibit 83: Mylan NV – Organizational developments
Exhibit 84: Mylan NV – Geographic focus
Exhibit 85: Mylan NV – Segment focus
Exhibit 86: Mylan NV – Key offerings
Exhibit 87: Mylan NV – Key customers
Exhibit 88: Pfizer Inc. – Vendor overview
Exhibit 89: Pfizer Inc. – Business segments
Exhibit 90: Pfizer Inc. – Organizational developments
Exhibit 91: Pfizer Inc. – Geographic focus
Exhibit 92: Pfizer Inc. – Segment focus
Exhibit 93: Pfizer Inc. – Key offerings
Exhibit 94: Pfizer Inc. – Key customers
Exhibit 95: Sanofi – Vendor overview
Exhibit 96: Sanofi – Business segments
Exhibit 97: Sanofi – Organizational developments
Exhibit 98: Sanofi – Geographic focus
Exhibit 99: Sanofi – Segment focus
Exhibit 100: Sanofi – Key offerings
Exhibit 101: Sanofi – Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors




【掲載企業】

AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[特発性頭蓋内圧亢進治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆